S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
Is Gold Really Boring? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
Is Gold Really Boring? (Ad)
US consumer confidence tumbles in September as American anxiety about the future grows
3 Household Names With RSIs That Scream Oversold
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
Is Gold Really Boring? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
Is Gold Really Boring? (Ad)
US consumer confidence tumbles in September as American anxiety about the future grows
3 Household Names With RSIs That Scream Oversold
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
Is Gold Really Boring? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
Is Gold Really Boring? (Ad)
US consumer confidence tumbles in September as American anxiety about the future grows
3 Household Names With RSIs That Scream Oversold
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
Is Gold Really Boring? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
Is Gold Really Boring? (Ad)
US consumer confidence tumbles in September as American anxiety about the future grows
3 Household Names With RSIs That Scream Oversold
NASDAQ:ASND

Ascendis Pharma A/S (ASND) Stock Forecast, Price & News

$94.21
-1.29 (-1.35%)
(As of 09/26/2023 ET)
Compare
Today's Range
$92.69
$96.54
50-Day Range
$86.50
$103.97
52-Week Range
$64.33
$134.52
Volume
331,333 shs
Average Volume
313,394 shs
Market Capitalization
$5.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$145.20

Ascendis Pharma A/S MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
54.1% Upside
$145.20 Price Target
Short Interest
Bearish
7.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.37mentions of Ascendis Pharma A/S in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($9.91) to ($8.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

526th out of 963 stocks

Pharmaceutical Preparations Industry

231st out of 448 stocks


ASND stock logo

About Ascendis Pharma A/S (NASDAQ:ASND) Stock

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

ASND Price History

ASND Stock News Headlines

The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
Short Interest in Ascendis Pharma A/S (NASDAQ:ASND) Declines By 5.0%
Ascendis Pharma A/S (NASDAQ:ASND) Shares Gap Up to $100.23
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Berenberg Bank Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
Here’s Why Ascendis Pharma A/S (ASND) Declined in Q2
See More Headlines
Receive ASND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ASND Company Calendar

Last Earnings
11/09/2021
Today
9/27/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ASND
Employees
797
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$145.20
High Stock Price Forecast
$192.00
Low Stock Price Forecast
$113.00
Forecasted Upside/Downside
+54.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$-614,450,000.00
Net Margins
-500.93%
Pretax Margin
-500.07%

Debt

Sales & Book Value

Annual Sales
$53.93 million
Book Value
$4.87 per share

Miscellaneous

Free Float
34,291,000
Market Cap
$5.38 billion
Optionable
Optionable
Beta
0.50
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Jan Moller Mikkelsen (Age 63)
    Pres, CEO, Member of Exec. Board & Exec. Director
  • Mr. Scott T. Smith (Age 49)
    CFO, Exec. VP & Member of Exec. Board
  • Ms. Lotte Sonderbjerg (Age 62)
    Exec. VP, Chief Admin. Officer & Member of the Exec. Board
  • Mr. Michael Wolff Jensen L.L.M. (Age 52)
    Exec. VP, Chief Legal Officer & Member of the Exec. Board
  • Mr. Peter Rasmussen (Age 54)
    VP of Fin. & Principal Accounting Officer
  • Mr. Timothy J. Lee
    Sr. Director of Investor Relations
  • Mr. Flemming Steen Jensen (Age 62)
    Exec. VP of Product Supply & Quality - Endocrinology Rare Diseases
  • Dr. Kennett Sprogoe Ph.D. (Age 44)
    Exec. VP of Research & Product Devel.
  • Dr. Birgitte Volck M.D. (Age 61)
    Ph.D., Exec. VP and Head of Clinical Devel. & Medical Affairs - Endocrinology Rare Diseases
  • Dr. Jens Sigurd Okkels Ph.D. (Age 62)
    Exec. VP of Product Devel.













ASND Stock - Frequently Asked Questions

Should I buy or sell Ascendis Pharma A/S stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ASND shares.
View ASND analyst ratings
or view top-rated stocks.

What is Ascendis Pharma A/S's stock price forecast for 2023?

10 Wall Street research analysts have issued 12-month price targets for Ascendis Pharma A/S's stock. Their ASND share price forecasts range from $113.00 to $192.00. On average, they anticipate the company's stock price to reach $145.20 in the next twelve months. This suggests a possible upside of 54.1% from the stock's current price.
View analysts price targets for ASND
or view top-rated stocks among Wall Street analysts.

How have ASND shares performed in 2023?

Ascendis Pharma A/S's stock was trading at $122.13 on January 1st, 2023. Since then, ASND shares have decreased by 22.9% and is now trading at $94.21.
View the best growth stocks for 2023 here
.

When is Ascendis Pharma A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our ASND earnings forecast
.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) posted its earnings results on Tuesday, November, 9th. The biotechnology company reported ($1.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.60) by $1.13. The biotechnology company had revenue of $1.31 million for the quarter, compared to analysts' expectations of $1.60 million. Ascendis Pharma A/S had a negative trailing twelve-month return on equity of 257.83% and a negative net margin of 500.93%. During the same quarter in the prior year, the firm earned ($2.70) EPS.

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by a number of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (19.58%), Artisan Partners Limited Partnership (10.85%), Davidson Kempner Capital Management LP (0.00%), Capital International Investors (3.48%), TimesSquare Capital Management LLC (1.34%) and Spyglass Capital Management LLC (1.15%).

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $94.21.

How much money does Ascendis Pharma A/S make?

Ascendis Pharma A/S (NASDAQ:ASND) has a market capitalization of $5.38 billion and generates $53.93 million in revenue each year. The biotechnology company earns $-614,450,000.00 in net income (profit) each year or ($11.30) on an earnings per share basis.

How many employees does Ascendis Pharma A/S have?

The company employs 797 workers across the globe.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The official website for the company is www.ascendispharma.com. The biotechnology company can be reached via phone at (457) 022-2244, via email at ir@ascendispharma.com, or via fax at 45-3694-4010.

This page (NASDAQ:ASND) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -